Sign in
ACORQ Stock Price, Chart, Stats & News
Acorda Therapeutics, Inc.
Save
Acorda Therapeutics, Inc. (ACORQ) does not currently pay a dividend.
12,421
Market cap
–
Current P/E
–
Forward P/E
ACORQ chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 60.86% |
Operating margin | -19.78% |
Pretax margin | -251.65% |
Net margin | -214.95% |
Effective tax rate | 14.58% |
ROA | -214.75% |
ROE | 786.07% |
D/E | -1.21x |
Interest coverage ratio | -0.74x |
ACORQ valuation
P/E | – |
P/S | 0.00x |
P/B | -0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | -0.00x |
EV multiple | 0.69x |
About
Acorda Therapeutics, Inc. operates as a biopharmaceutical enterprise focused on researching, developing, and bringing to market medical treatments for neurological conditions, predominantly in the United States. The company offers Ampyra (dalfampridine), an oral medication aimed at enhancing walking capabilities in adult patients experiencing multiple sclerosis. Furthermore, it sells Inbrija, an inhaled formulation of levodopa, which is prescribed for the temporary management of "OFF" episodes in individuals with Parkinson's disease who are already on a carbidopa/levodopa regimen.
Similar securities
Based on sector and market capitalization
Report issue